StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy

Nine analysts raise stock price targets for Apellis Pharmaceuticals after it wins the FDA's first approval for a geographic atrophy therapy.

Related Keywords

,Peter Stein ,Raymond James ,Iveric Bio ,Annabel Samimy ,Steven Seedhouse ,Yigal Nochomovitz ,Robertw Baird ,Laura Chico ,Chris Howerton ,Chirinjeev Kathuria ,Doug Tsao ,Colleen Kusy ,Tazeen Ahmad ,Jackk Allen ,Brian Culley ,Ib Chemoprotection ,Office Of New Drugs ,Genentech ,Apellis Pharmaceuticals ,Goldman Sachs ,Evercore Group ,Citigroup ,Approval Commences ,New Era ,New Drug Application ,Priority Review ,Prescription Drug User Fee Act ,Bofa Securities ,Lineage Cell Therapeutics ,Phase Ib Chemoprotection ,Formal Dispute Resolution Request ,Complete Response Letter ,New Drugs ,